Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma

Published:2022-07-21 Issue:2 Volume:30 Page:121-124
ISSN:1344-6835
Container-title:Annals of Cancer Research and Therapy
language:en
Short-container-title:Ann. Cancer Res. Therap.

Author:

Hoshi Keisuke¹,Hirano Kazuhiko²,Tsukamoto Kasumi¹,Abe Yukiko¹,Tsuchiya Maya¹,Sasaki Yoshihiro³,Mouri Atsuto¹,Suhara Kozo¹,Kamimura Mitsuhiro¹

Affiliation:

1. Department of Pulmonology, National Hospital Organization Disaster Medical Center

2. Department of Clinical Pathology, National Hospital Organization Disaster Medical Center

3. Department of Gastroenterology, National Hospital Organization Disaster Medical Center

Publisher

The Japanese Society of Strategies for Cancer Research and Therapy

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://www.jstage.jst.go.jp/article/acrt/30/2/30_121/_pdf

Reference27 articles.

1. 1) Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33. doi: 10.1056/NEJMoa1606774

2. 2) Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J. 2017;4(1):e57. doi: 10.14309/crj.2017.57

3. 3) Horisberger A, La Rosa S, Zurcher JP, et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer. 2018;6(1):1-7.

4. 4) Sajjan S, Savant D, Thomas R, et al. A very rare case of esophagitis due to nivolumab immunotherapy. Am J Med Case Rep. 2019;7(6):97-9.

5. 5) Kambhampati S, Bauer KE, Bracci PM, et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer. 2019;125(18):3234-41.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab/prednisolone;Reactions Weekly;2023-01-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3